Outcomes of Elderly Patients Hospitalized with the SARS-CoV-2 Omicron B.1.1.529 Variant: A Systematic Review

The Omicron (B.1.1.529) variant of the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) had an increased rate of spreading among the general population. Although this virus mutation resulted in milder symptoms, those on the vulnerable side of the population are still in danger of developing severe symptoms. Thus, this systematic review focused on identifying the clinical outcomes of older age patients (>65) that are hospitalized with the SARS-CoV-2 Omicron variant. The research was conducted using four electronic databases (PubMed, Scopus, Web of Science, and ProQuest Central), with a search query in December 2022 that comprised the duration of the COVID-19 pandemic. The inclusion criteria comprised (1) a population of patients older than 65 years, (2) a history of hospitalization for SARS-CoV-2 infection, and (3) infection with Omicron B.1.1.529 variant. The initial search generated 295 articles, out of which six were included in the systematic review, and a total of 7398 patients. The main findings were that when looking at the elderly population, the mortality and hospitalization rates remained high. This is because older people are more vulnerable and have more comorbidities that interfere with the virus’s progress. However, there is inconsistency in mortality rates, since the data reported by the included studies had different selection criteria based on the severity of the COVID-19 infection. Although no statistically significant differences were found between the unvaccinated and vaccinated groups, patients who got booster doses of vaccination had a lower likelihood of developing severe symptoms, serving as a protective factor for this population.

[1]  V. Čokić,et al.  Three Outbreaks of COVID-19 in a Single Nursing Home over Two Years of the SARS-CoV-2 Pandemic , 2023, Aging and disease.

[2]  Wassan Nori,et al.  Omicron targets upper airways in pediatrics, elderly and unvaccinated population , 2022, World journal of clinical cases.

[3]  Jianquan Li,et al.  Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report , 2022, Medicine.

[4]  N. Chiu,et al.  Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic , 2022, Expert review of vaccines.

[5]  A. Palamara,et al.  Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study , 2022, Vaccine.

[6]  Xu Dong,et al.  Disease Progression of Hospitalized Elderly Patients with Omicron BA.2 Treated with Molnupiravir , 2022, Infectious Diseases and Therapy.

[7]  Guangyou Duan,et al.  Older age and depressive state are risk factors for re-positivity with SARS-CoV-2 Omicron variant , 2022, Frontiers in Public Health.

[8]  O. Launay,et al.  COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness , 2022, Viruses.

[9]  C. Fan,et al.  Identification of CKD, bedridden history and cancer as higher-risk comorbidities and their impact on prognosis of hospitalized Omicron patients: a multi-centre cohort study , 2022, Emerging microbes & infections.

[10]  Rosana Pelayo,et al.  Decrease in COVID-19 adverse outcomes in adults during the Delta and Omicron SARS-CoV-2 waves, after vaccination in Mexico , 2022, Frontiers in Public Health.

[11]  W. Schaffner,et al.  COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022 , 2022, JAMA internal medicine.

[12]  Chuanlong Zhu,et al.  The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial , 2022, Frontiers in Medicine.

[13]  M. Moret,et al.  Retrospective Cohort Study of COVID-19 in Patients of the Brazilian Public Health System with SARS-CoV-2 Omicron Variant Infection , 2022, Vaccines.

[14]  P. Austin,et al.  Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes , 2022, JAMA network open.

[15]  Nathan R. Shively,et al.  Description of Hospitalizations due to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Based on Vaccination Status , 2022, Open forum infectious diseases.

[16]  Jiming Zhang,et al.  Proportion of asymptomatic infection and nonsevere disease caused by SARS‐CoV‐2 Omicron variant: A systematic review and analysis , 2022, Journal of medical virology.

[17]  Jing-wen Ai,et al.  Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave , 2022, Emerging microbes & infections.

[18]  R. Kohli-Seth,et al.  The fourth wave: vaccination status and intensive care unit mortality at a large hospital system in New York City , 2022, Acute and critical care.

[19]  F. Alhumaydhi,et al.  Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2? , 2022, Biomedicine & Pharmacotherapy.

[20]  T. Saltykova,et al.  Clinical and epidemiological characteristics of hospitalized patients with COVID-19 during different pandemic periods in Moscow , 2022, Journal of microbiology, epidemiology and immunobiology.

[21]  N. Pearce,et al.  Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil , 2022, Nature Communications.

[22]  R. Bellomo,et al.  Clinical Characteristics and Outcomes of Critically Ill Patients with 1, 2 and 3 doses of Vaccination against COVID‐19 in Australia , 2022, Internal medicine journal.

[23]  Jue Liu,et al.  The Association between Risk Perception and Hesitancy toward the Booster Dose of COVID-19 Vaccine among People Aged 60 Years and Older in China , 2022, Vaccines.

[24]  E. Leung,et al.  SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients? , 2022, The Journal of Allergy and Clinical Immunology: In Practice.

[25]  R. Brondeel,et al.  Clinical Severity of SARS-CoV-2 Omicron Variant Compared with Delta among Hospitalized COVID-19 Patients in Belgium during Autumn and Winter Season 2021–2022 , 2022, Viruses.

[26]  P. Cheung,et al.  Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis , 2022, BMJ.

[27]  A. Nouvenne,et al.  Defining SARS-CoV-2 breakthrough infection needing hospitalization in mass vaccination era: from disease-centered to patient-centered care , 2022, Acta bio-medica : Atenei Parmensis.

[28]  E. Orenbuch-Harroch,et al.  Hospitalized patients with severe COVID-19 during the Omicron wave in Israel – benefits of a fourth vaccine dose , 2022, medRxiv.

[29]  J. L. Bernal,et al.  Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study , 2022, Nature Communications.

[30]  U. Malmqvist,et al.  Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities – surveillance results from southern Sweden, July 2021 to January 2022 , 2022, medRxiv.

[31]  S. Zeger,et al.  Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.

[32]  Md. Rabiul Islam,et al.  New Coronavirus Variants are Creating More Challenges to Global Healthcare System: A Brief Report on the Current Knowledge , 2022, Clinical pathology.

[33]  R. Mukherjee,et al.  Why are some coronavirus variants more infectious? , 2021, Journal of Biosciences.

[34]  Michael J. Hogan,et al.  mRNA Vaccines in the COVID-19 Pandemic and Beyond. , 2021, Annual review of medicine.

[35]  K. Hirayama,et al.  Quality assessment tools used in systematic reviews of in vitro studies: A systematic review , 2021, BMC Medical Research Methodology.

[36]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[37]  C. Dolea,et al.  World Health Organization , 1949, International Organization.